Memorial Hermann has been recognized for its overall performance in serving both individuals and the community. Photo via memorialhermann.org

Houston hospitals have been evaluated by a new ranking to determine the institutions that are doing their best to serve their patients and the community as a whole.

Brookline, Massachusetts-based think tank, The Lown Institute, has revealed its national rankings on its Lown Institute Hospitals Index — which evaluated hospitals based on civic leadership (based on inclusion and access), value of care, and patient outcomes (which evaluates safety and satisfaction).

"At a time when communities are relying on them like never before, hospitals must rethink what it means to be great," says Dr. Vikas Saini, president of the Lown Institute, in a news release. "COVID-19 highlights how hospitals are essential community partners for anyone in need. To be great, however, a hospital cannot only provide care that's high in quality. It must also deliver value and advance equality. Our index is designed to help them do just that."

The Texas Medical Center's Memorial Hermann Hospital ranked as No. 9 on the list that evaluated over 3,000 hospitals in the country. The hospitals are also given a grade on each of the three categories. Memorial Hermann received an A for civic leadership, an A- for value of care, and an A+ for patient outcomes — for an overall A+ grade.

Based on ranking, the Houston area's top 10 hospitals, which all received an overall grade of A- or above, are:

  1. Memorial Hermann Texas Medical Center (No. 9 in the country; No. 3 in the state)
  2. Harris Health System (No. 23 in the country; No. 5 in the state)
  3. Memorial Hermann Northeast Hospital in Humble (No. 165 in the country; No. 15 in the state)
  4. Memorial Hermann Hospital System (No. 297 in the country; No. 17 in the state)
  5. Brazosport Regional Health System in Lake Jackson (No. 304 in the country; No. 18 in the state)
  6. The Woman's Hospital of Texas (No. 373 in the country; No. 25 in the state)
  7. Memorial Hermann Katy Hospital in Katy (No. 374 in the country; No. 26 in the state)
  8. Houston Methodist San Jacinto Hospital in Baytown (No. 627 in the country; No. 43 in the state)
  9. Memorial Hermann Sugar Land Hospital in Sugar Land (No. 648 in the country; No. 44 in the state)
  10. Memorial Hermann Memorial City Medical Center (No. 652 in the country; No. 45 in the state)

The Harris Health System ranked the highest in Houston for civic leadership, and the Memorial Hermann Memorial City Medical Center scored the highest in the region for patient outcomes.

There were three other Texas hospitals among the top 10 in the nation — JPS Health Network in Fort Worth ranked as No. 1, Seton Northwest Hospital in Austin ranked as No. 4, and Parkland Health and Hospital System in Dallas ranked as No. 10.

The point of the study, according to the release, is to hold hospitals accountable for more than just one factor of success.

"There are some very fine hospitals that feel forced to focus on profitable elective procedures to stay in business," says Saini in the release. "This can lead to business decisions that make them look good on outcomes like mortality, but at the expense of equity. The data show that gaps between a hospital's clinical results and its performance in the community are sometimes very wide, which can contribute to disparities in care and put certain communities at risk."

The study factored in data from a variety of sources, including the 100 percent Medicare claims datasets (MEDPAR and outpatient); Internal Revenue Service pulled from Community Benefit Insight database; Healthcare Cost Report Information System administered by the Centers for Medicare and Medicaid Services; Securities and Exchange Commission filings; public records; Bureau of Labor Statistics; and other databases, according to the release.

"No other hospital ranking provides a 360-degree view of hospital performance," says Shannon Brownlee, senior vice president at the Lown Institute, in the release. "Many of the best-known hospitals score highly on patient outcomes but poorly on civic leadership and value of care. Our data show that it's possible to do well in all three categories, because some hospitals are doing it. That means all the people in their communities are being served effectively and fairly."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”